Shufeng Xingbi Therapy Restores Th1/Th2 Balance in Allergic Rhinitis Rats

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent chronic inflammatory condition of the nasal mucosa, affecting over 10% of the global population and marked by paroxysmal sneezing, nasal congestion, rhinorrhea, and itching. Its pathogenesis is primarily attributed to an imbalance between Th1 and Th2 immune responses, with excessive Th2 activity promoting IgE-mediated hypersensitivity. Conventional therapeutics—including glucocorticoids, antihistamines, and leukotriene antagonists—offer symptomatic relief but are often limited by adverse effects and incomplete disease control, especially in pediatric populations. Recent research emphasizes the role of the gut microbiota and its metabolites, such as short-chain fatty acids (SCFAs), in modulating allergic and immune responses, reinforcing the importance of the gut-immune axis.

The reference study (Yan et al., 2025) investigates whether Shufeng Xingbi Therapy (SFXBT), a traditional Chinese medicine regimen, can restore Th1/Th2 balance and beneficially alter intestinal flora in an established rat model of allergic rhinitis. The research question centers on elucidating the immunomodulatory and microbiome-targeted mechanisms of SFXBT in allergic airway inflammation.

Key Innovation from the Reference Study

The central innovation of this study lies in its integrative approach—simultaneously assessing mucosal immune status, systemic cytokines, and gut microbiota composition in response to SFXBT. The authors combine behavioral scoring with advanced molecular and microbial profiling to reveal that SFXBT not only reduces AR symptoms, but also rebalances immune signaling and fosters a beneficial shift in intestinal flora. This mechanistic link between TCM-based therapy, immune modulation, and the microbiome provides a comprehensive experimental framework for future translational research in allergic disorders (Yan et al., 2025).

Methods and Experimental Design Insights

The study utilized 32 male Sprague–Dawley rats (6 weeks old, 200–250g), randomized into four groups: control, OVA-sensitized AR, antibiotic + SFXBT, and acetic acid + SFXBT. The AR model was induced by ovalbumin (OVA) sensitization and challenge—a well-established protocol for mimicking human allergic rhinitis. SFXBT was administered both orally (Shufeng Xingbi recipe) and topically (Xingbi gel nasal drops), reflecting clinical practice.

Key experimental assessments included:

• Behavioral scoring of AR symptoms.
• Histopathological examination of nasal mucosa (H&E staining).
• 16S rDNA sequencing of colonic content for microbial profiling.
• Quantification of serum IgE, IL-4, and SCFAs by ELISA.
• Gene expression analysis (STAT5, STAT6, GATA3) in nasal mucosa using RT-qPCR.
• Protein expression analysis (IL-4, STAT5, STAT6, GATA3) via Western blotting.

This multifaceted approach enabled the authors to correlate changes in immune status with alterations in gut microbial communities and metabolic profiles.

Protocol Parameters

• OVA sensitization: Rats receive intraperitoneal injection of OVA to establish AR model, followed by repeated nasal OVA challenge.
• Antibiotic pretreatment: Antibiotic group receives defined antibiotics prior to SFXBT administration to assess microbiome-dependent effects.
• SFXBT administration: Oral Shufeng Xingbi recipe combined with Xingbi nasal gel; dosage and frequency per experimental arm.
• Sample collection: Fecal samples for 16S rDNA, serum for cytokines/SCFAs, nasal tissue for histology and molecular assays.

Core Findings and Why They Matter

The study's principal findings can be summarized as follows (Yan et al., 2025):

• AR behavioral scores and nasal mucosal inflammation were markedly reduced in both the antibiotic + SFXBT and acetic acid + SFXBT groups versus OVA alone (P < 0.01).
• Microbiome analysis showed a significant increase in fecal Firmicutes and a decrease in Bacteroidetes. At the genus level, Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were enriched post-treatment.
• Serum IgE and IL-4 levels—key markers of Th2 bias—were significantly decreased, while SCFA concentrations rose in SFXBT-treated groups (P < 0.05).
• Expression of STAT5, STAT6, and GATA3 (both mRNA and protein)—critical for Th2 cell differentiation and activity—was downregulated in nasal mucosa following SFXBT therapy.

Collectively, these results highlight the dual impact of SFXBT: direct suppression of allergic inflammation via Th1/Th2 rebalance, and indirect modulation through restoration of a health-associated intestinal microbiome and its metabolites. The enrichment of Lactobacillus is consistent with prior findings that probiotic species and their metabolites (such as SCFAs) can promote regulatory immune responses and ameliorate allergic pathology, as seen in related studies on gut-immune interactions (Deng et al., 2024).

Comparison with Existing Internal Articles

Several internal articles provide valuable mechanistic parallels and methodological strategies relevant to this study:

• Neomycin Sulfate in Nucleic Acid and Ion Channel Assays demonstrates how aminoglycoside antibiotics like neomycin sulfate can be used to dissect RNA/DNA structure-function relationships and ion channel modulation, supporting advanced immune and microbiome research protocols.
• Lactobacillus acidophilus and UDCA Modulate Immunity in UC explores the beneficial effects of microbiota-derived metabolites on immune regulation, echoing the current study's findings on SCFA-mediated immune homeostasis.
• Neomycin Sulfate: Mechanistic Precision and Strategic Opportunities discusses the translational utility of aminoglycoside antibiotics in immune-microbiome research, relevant for studies employing antibiotics to manipulate the gut flora as in the present protocol.

While the primary focus of Yan et al. (2025) is on herbal therapy, these resources highlight the growing intersection of microbiome, immune, and nucleic acid research tools—including the use of aminoglycoside antibiotics for targeted microbiome modulation or RNA/DNA structure interaction studies.

Limitations and Transferability

Despite its methodological rigor, this study has several limitations:

• The findings are restricted to a rat model of OVA-induced AR and may not fully extrapolate to human disease.
• The specific molecular constituents of SFXBT responsible for observed effects remain to be identified.
• Long-term safety, optimal dosing, and translational relevance to clinical AR require further investigation.
• Antibiotic pretreatment, while clarifying microbiome contributions, can also introduce off-target effects, warranting careful interpretation.

These caveats should guide future study design and cautious application in translational research.

Why this cross-domain matters, maturity, and limitations

The integration of immune, microbiome, and nucleic acid-targeted interventions is increasingly recognized as essential for unraveling complex allergic and inflammatory diseases. The current study and related internal resources illustrate how manipulating gut flora—whether with traditional therapies, probiotics, or aminoglycoside antibiotics—can reprogram immune responses. However, the maturity of such cross-domain strategies varies, and translation from preclinical models to human application is not straightforward. Further, while tools like neomycin sulfate are valuable for RNA/DNA structure interaction studies and controlled microbiome modulation, their use in vivo must balance efficacy with specificity and safety.

Research Support Resources

To enable robust investigation of RNA/DNA structure interactions, gut-immune modulation, and related molecular workflows, researchers may consider incorporating Neomycin sulfate (SKU B1795) from APExBIO. As a well-characterized aminoglycoside antibiotic, neomycin sulfate is widely employed in studies requiring disruption of RNA-protein interactions, DNA triplex stabilization, and targeted microbiome modification. Its defined mechanism of action and high purity make it suitable for mechanistic immune and microbiota research, as demonstrated in protocols analogous to those described above. For detailed experimental guidance and troubleshooting, consult the referenced internal articles or the product information linked above.